Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-31
2007-07-31
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S394000, C546S199000, C548S304700, C548S309400
Reexamination Certificate
active
11168107
ABSTRACT:
Aryl substituted benzimidazole and imidazo[4,5]pyridine ethers are described as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.
REFERENCES:
patent: 5059621 (1991-10-01), Shroot et al.
patent: 5814651 (1998-09-01), Duplantier et al.
patent: 2005/0070550 (2005-03-01), Arienti et al.
patent: 0148431 (1985-07-01), None
patent: 0209707 (1987-01-01), None
patent: 0719765 (1996-07-01), None
patent: WO 98/06703 (1998-02-01), None
patent: WO 99/11627 (1999-03-01), None
patent: WO 99/61019 (1999-12-01), None
patent: WO 99/61020 (1999-12-01), None
patent: WO 01/21771 (2001-03-01), None
patent: WO 01/98465 (2001-12-01), None
patent: WO 02/072090 (2002-09-01), None
patent: WO 03/011219 (2003-02-01), None
patent: WO 03/032984 (2003-04-01), None
Tominaga, K. et al. Role of Human Cds1 (Chk2) Kinase in DNA Damage Checkpoint and Its Regulation by p53. J. Biol. Chem. 1999, 274(44), 31463-31467.
Matsuoka, S. et al. Linkage of ATM to Cell Cycle Regulation by the Chk2 Protein Kinase. Science 1998, 282, 1893-1897.
Blasina, A. et al. A Human Homologue of the Checkpoint Kinase Cds1 Directly Inhibits Cdc25 Phosphatase. Curr. Biol. 1999, 9(1), 1-10.
Lee, J.-S. et al. hCds1-Mediated Phosphorylation of BRCA1 Regulates the DNA Damage Response. Nature 2000, 404, 201-204.
Falck, J. et al. The ATM-Chk2-Cdc25A Checkpoint Pathway Guards against Radioresistant DNA Synthesis. Nature 2001, 410, 842-847.
Buscemi, G. et al, Chk2 Activation Dependence on Nbs1 after DNA Damage. Mol. Cell. Biol. 2001, 21(15), 5214-5222.
Hirao, A. et al. Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner Mol. Cell. Biol. 2002, 22(18), 6521-6532.
Takai, H. et al. Chk2-Deficient Mice Exhibit Radioresistance and Defective p53-Mediated Transcription. EMBO J. 2002, 21(19), 5195-5205.
White, A.W et al. Resistance-Modifying Agents. 9. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase. J. Med. Chem. 2000, 43(22), 4084-4097.
Kim, J.S. et al. Structure-Activity Relationships of Benzimidazoles and Related Heterocycles as Topoisomerase I Poisons. Bioorg. Med. Chem. 1996, 4(4), 621-630.
McClure, K.J. et al. Novel Non-Benzimidazole Chk2 Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2006, in press.
Arienti, K.L. et al. Checkpoint Kinase Inhibitors: SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles. J. Med. Chem. 2005, 48, 1873-1885.
International Search Report dated Dec. 5, 2005, for corresponding international application PCT/US2005/023004.
Breitenbucher J. Guy
Lee-Dutra Alice
Neff Danielle K.
Harbour John
Janssen Pharmaceutica N.V.
Kosack Joseph R.
Saeed Kamal A.
LandOfFree
Aryl-substituted benzimidazole and imidazopyridine ethers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl-substituted benzimidazole and imidazopyridine ethers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl-substituted benzimidazole and imidazopyridine ethers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3744792